Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02511106 · OUTCOME

Overall Survival Rate at 2, 3 and 5 Years

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

What was measured

Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.

Analysis population: Full Analysis Set (FAS) stage IB-IIIA patients

Groups in this outcome

AZD9291 80mg Tablet

Taken once daily

Placebo Tablet

Taken once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD9291 80mg Tablet339
Placebo Tablet343

Reported measurements

OS rate at 2 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet99.4Not reported97.599.8Not reported
Placebo Tablet94.3Not reported91.296.3Not reported
OS rate at 3 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet95.3Not reported92.397.1Not reported
Placebo Tablet88.8Not reported84.991.8Not reported
OS rate at 5 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet87.6Not reported83.390.9Not reported
Placebo Tablet77.7Not reported72.781.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        97.5
        upper Limit
        99.8
        value
        99.4
      2. group Id
        OG001
        lower Limit
        91.2
        upper Limit
        96.3
        value
        94.3
    title
    OS rate at 2 years (%)
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        92.3
        upper Limit
        97.1
        value
        95.3
      2. group Id
        OG001
        lower Limit
        84.9
        upper Limit
        91.8
        value
        88.8
    title
    OS rate at 3 years (%)
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        83.3
        upper Limit
        90.9
        value
        87.6
      2. group Id
        OG001
        lower Limit
        72.7
        upper Limit
        81.9
        value
        77.7
    title
    OS rate at 5 years (%)
denoms
  1. counts
    1. group Id
      OG000
      value
      339
    2. group Id
      OG001
      value
      343
    units
    Participants
description
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
dispersion Type
95% Confidence Interval
groups
  1. description
    Taken once daily
    id
    OG000
    title
    AZD9291 80mg Tablet
  2. description
    Taken once daily
    id
    OG001
    title
    Placebo Tablet
param Type
NUMBER
population Description
Full Analysis Set (FAS) stage IB-IIIA patients
reporting Status
POSTED
time Frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
title
Overall Survival Rate at 2, 3 and 5 Years
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice